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In this issue of Cancer Cell, Rad and colleagues report findings that underscore the importance of oncogenic
BRAFmutation coupledwithmicrosatellite instability, p16Ink4a inactivation, and p53mutation in the serrated
pathway of colon cancer development. These findings provide translational insights into potential therapeu-
tic intervention for BRAF mutant colon cancers.Colorectal cancer (CRC) is a commonma-
lignancy in the United States (US) and
worldwide. Whereas CRC incidence has
been declining steadily over the past
decade in the US, mortality remains high
and unchanged with over 50,000 deaths
annually, which is attributable largely to
complications of metastatic disease.
The molecular genetics of hereditary
and sporadic CRC have been a paradigm
for cancer biology investigation in general
over the last 25 years (Fearon, 2011;
Rustgi 2007). The majority of CRCs have
either inactivating mutations in the APC
tumor suppressor gene or activating
mutations in the b-catenin gene that result
in stabilization and nuclear translocation
of b-catenin, which in turn cooperates
with TCF transcriptional factors to acti-
vate a repertoire of genes involved in cell
proliferation and growth. Many CRCs
involve subsequent mutations in KRAS,
TP53, and SMAD4. Comprehensive
genomic analyses are expanding the
number of genes identified with somatic
mutations (Muzni et al., 2012). These clas-
sical CRCs often display chromosomal
instability (CIN). Another subset of CRCs
displays microsatellite instability (MIN).
Inactivation of mismatch repair genes
(MLH1, MSH2, MSH6, and PMS2)
through mutation or hypermethylation
results in MIN. Based on the extent of
microsatellite instability (MSI), CRCs can
be classified as MSI-high, MSI-low, or
microsatellite stable (MSS). CRCs with
CIN are often MSS.
A less common molecular pathogen-
esis pathway of sporadic CRC is the
serrated pathway, meaning the progres-
sion of sessile serrated adenoma (SSA)and traditional serrated adenomas
(TSAs) to colorectal cancer, typically
(albeit not exclusively) in the proximal or
right colon (Leggett and Whitehall, 2010).
The term serrated is used due to the
‘‘sawtooth’’ appearance of the crypt
epithelium within these polyps. SSAs are
highlighted by the presence ofBRAF point
mutation (V600E), leading to enhanced
signaling through MEK and ERK, which
occurs also with KRAS mutation. Yet,
classic adenomas are not associated
with BRAF mutation. Another remarkable
feature of SSAs is the CpG island methyl-
ator phenotype (CIMP), which fosters the
transition of microvesicular hyperplastic
polyps to SSAs and eventually to cancer.
One key target appears to be methylation
of MLH1, resulting in MSI-high colon
tumors. Yet, the progression of SSAs to
cancer is kept in abeyance by p16INK4a-
mediated senescence as well as intact
p53. Overcoming p16INK4a and p53 tumor
suppressor activities are likely critical in
the ultimate progression to cancer.
Can the serrated pathway be modeled
in vivo? In a comprehensive study by
Rad et al. (2013) in this issue of Cancer
Cell, conditional BrafV637E (the murine
counterpart to human BRAFV600E)
knock-in mice were generated and
crossed to Villin-Cre transgenic mice
such that expression of the oncogene
would be restricted to small intestinal
and colonic epithelia. The resulting dou-
ble mutant mice developed serrated
polyps, which are characterized by hyper-
proliferation (expansion to mid-upper
crypts) but not apoptosis. In an age-
dependent fashion, the hyperplasias pro-
gressed to dysplasias, and TSAs, but notCancerSSAs, emerged. This might be attributed
to the mouse’s small intestine’s predilec-
tion for the polyps, because SSAs in pa-
tients tend to be colonic. As such, the au-
thors refer to the small intestinal lesions as
murine serrated adenoma (mSA) with
either low-grade dysplasia (mSA-LGD) or
high-grade dysplasia (mSA-HGD). In
16% of the mice, dysplasia progressed
to invasive carcinomas (5/31). Not sur-
prisingly, but importantly, nearly 40%
(13/33) of theBrafV637EmSAs and cancers
were MSI-high; by contrast, the mSHs
were either MSS or MSI-low.
Given the long latency for cancer for-
mation,Villin-Cre;BrafV637E/+;p53LSL-R172H/+
mice were generated to evaluate the
functional consequences of introducing
mutant p53. In this context, 56% of the
compound mutant mice between 10–
20 months developed carcinomas, with
the average number of cancers being 5.2
times higher than in Villin-Cre;BrafV637E/+
mice. These findings underscore the
importance of p53 inactivation in late-
stage carcinogenesis in the serrated
pathway.
As p16Ink4a was induced in mSA-HGD
lesions in this study, the authors gener-
ated Villin-Cre;BrafV637E/+ mice with
homozygous p16Ink4a mutation to deter-
mine if senescence was present con-
comitantly. These p16Ink4a -deficient
compound mutant mice displayed a
substantial increase (6.4 times higher) in
carcinomas compared to mice with
p16Ink4a expression. Of note, mSAs and
carcinomas had elevated ERK activation
as well as enhanced WNT pathway
activation, as revealed by diffuse or
focal nuclear b-catenin accumulation.Cell 24, July 8, 2013 ª2013 Elsevier Inc. 1
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and Lrp1b, all components of WNT
signaling, accounting for b-catenin redis-
tribution. In summary, this study estab-
lishes genetic proof that Braf oncogenic
mutation can induce formation of mSHs,
mSAs, and a low penetrance of carci-
nomas, with the latter two lesions display-
ing MSI-high. The carcinoma progression
can be accelerated by p53 mutation or
p16Ink4a inactivation.
How do these findings compare to
oncogenic Kras mutation in the small in-
testine and colon? Oncogenic KrasG12D
expression driven by a transgenic Villin
promoter induces a spectrum of lesions,
ranging from aberrant crypt foci to inva-
sive adenocarcinomas without acquisi-
tion of Apc mutations, although there is
evidence of occasional p53 mutation in
this context (Janssen et al., 2002). In addi-
tion,CDX2P-G22Cre;KrasLSL-G12Dmutant
mice revealed epithelial hyperplasia and
crypt architecture changes in the colon,
reminiscent of those seen in human
hyperplastic polyps (Feng et al., 2011).
However, neither TSAs nor SSAs
emerged. More recently, Greten and col-
leagues found in a thorough study that in-
testinal epithelia-specific expression of
oncogenic KrasG12D in mice induced
serrated hyperplasia, which was charac-
terized by p16Ink4a overexpression and
senescence induction (Bennecke et al.,
2010). Deletion of Cdkn2a (the locus en-
coding p16Ink4a and p19Arf) in KrasG12D-
expressing mice prevented senescence
and led to invasive, metastasizing carci-
nomas. However, unlike the oncogenic
BRAF-driven tumors in the Rad et al.
(2013) study, these tumors were neither
MSI-high nor showed WNT pathway acti-
vation, generally speaking. Perhaps, we2 Cancer Cell 24, July 8, 2013 ª2013 Elseviecan surmise two pathways that cause
the induction of serrated adenomas,
recognizing that geographic location
(small intestine versus colon) and meticu-
lous morphological analysis are important
to distinguish murine lesions from human
lesions. The predominant initiating event
is Braf mutation; conceivably, intestinal
crypts are permissive for this oncogenic
insult. Kras mutation can occur as an
‘‘alternative’’ pathway, but is, perhaps,
less tolerated. Regardless, p16Ink4a in-
duction and likely senescence occur in
both settings; overcoming this is critical
for carcinoma initiation. However, MSI
may be divergent, with MSI-high being
much more prevalent in oncogenic
BRAF-induced lesions compared to
oncogenic Kras-induced lesions. Addi-
tionally, amplified MAPK signaling is
apparent in both scenarios, which may
have an impact on consideration of the
types of therapeutic intervention(s).
Rad et al. (2013) demonstrate efficacy
with MEK inhibition and combinatorial
BRAF/PI3K inhibition in cancer cell lines
and xenografts, which are resistant to
BRAF inhibitor therapy. This may prove
promising given the elusiveness of clinical
efficacy with BRAF inhibition in selected
colon cancers, to date, which is in
contrast to the 50%–60% response of
metastatic melanomas (Sullivan and Flah-
erty, 2013). Indeed, there is intense inves-
tigation to understand why resistance to
BRAF inhibition is present in colon cancer.
One answer may be due to feedback sig-
nals resulting in amplified EGFR signaling
(Prahallad et al., 2012). Another reason
may be due to the persistence of ampli-
fied ERK signaling, which may represent
a rationale for the ongoing development
of ERK-specific inhibitors apart from ther Inc.implementation of MEK inhibitors. Com-
parison of the commonalities and differ-
ences in BRAF inhibition between CRC
and melanoma may help in elucidating
mechanisms underlying intrinsic and
acquired resistance. Mouse models, like
the serrated intestinal cancer model
reported by Rad et al. (2013), will surely
aid these investigations and support
application of that knowledge preclinically
and clinically.REFERENCES
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